Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Buy, Sell Or Hold: L&T, Avenue Supermarts, Canara Bank, Uno Minda And Lupin — Ask Profit
Market experts shared buy, sell and hold recommendations for an array of stocks.
Pharma stocks: Lupin, Torrent hit new peaks; Sun nears summit; here's why
Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.
IndusInd Bank among 6 stocks to hit 52-week highs & rally up to 25% in a month
Six BSE 100 stocks, including Cholamandalam Investment, IndusInd Bank and Lupin, touched fresh 52-week highs as the Sensex climbed 521 points. The milestone reflects strong buying interest, positive momentum and growing investor confidence amid the broader market rally.
Top Gainers & Losers on 3 July: Zensar Tech, HFCL, IndusInd Bank, Muthoot Finance, Lupin among top gainers - livemint.com
Top Gainers & Losers on 3 July: Zensar Tech, HFCL, IndusInd Bank, Muthoot Finance, Lupin among top gainerslivemint.com
Stocks to Watch today: Bharti Airtel, Lupin, CSM Technologies, Coal India
Stocks to Watch today, July 2, 2026: Hero MotoCorp, Tata Technologies, Medi Assist Healthcare, and NLC India are among the top stocks to remain in focus during today's trading session.
Stocks to Watch for July 2: Coal India, Bharti Airtel, NMDC, Lupin, Indian Bank and more
From Bharti Airtel's NBFC launch to Lupin's EMA approval and Coal India's operational update, here are the stocks to track ahead of Thursday's trading session.
Lupin gets EU approval to expand rare disease drug NaMuscla to children
Lupin has received European Medicines Agency (EMA) approval to expand the use of its rare disease drug NaMuscla to pediatric patients with non-dystrophic myotonic disorders. The approval also includes two new dosage strengths, broadening treatment options for children, adolescents and adults across Europe.
Lupin receives EMA approval for Pediatric Indication of NaMuscla
Lupin gains as receives USFDA tentative nod for generic Xtandi tablets
Lupin rose 2.21% to Rs 2,393.80 after it has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in strengths of 40 mg, 80 mg, 120 mg, and 160 mg.
Lupin gets tentative US FDA nod for a generic prostate cancer drug
According to the company, the US FDA has found Lupin's 40 mg and 80 mg tablets to be bioequivalent to Astellas Pharma's reference listed drug Xtandi for the approved indications.
Lupin gets USFDA tentative approval for prostate cancer treatment drug
Indian pharmaceutical giant Lupin Ltd has secured tentative approval from the US FDA for its generic enzalutamide tablets, a crucial treatment for advanced prostate cancer. This approval covers multiple strengths, including 40 mg, 80 mg, 120 mg, and 160 mg. The company's offering is bioequivalent to the reference drug, Xtandi, and aims to provide more flexible dosing options for patients and medical professionals.
Lupin gets USFDA tentative nod for generic Xtandi tablets
Lupin said it has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in strengths of 40 mg, 80 mg, 120 mg, and 160 mg.